| Trial Name: |
E 5202
|
| Intro: |
A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers |
| Condition: |
|
| Description: |
This research study is being done to find out whether specific biological features (often called tumor markers or markers) seen in tests done on a colon tumors can be used to predict recurrence of tumors in patients with stage II colon cancer. The chemotherapy drugs given in combination in this study are 5-fluorouracil (5-FU), leucovorin and oxaliplatin. Researchers will look to see if adding bevacizumab to these other cancer-fighting agents is better for treating colon cancer patients, who may be at increased risk for recurrence based on the markers shown in their tumors. Researchers also want to see if adding bevacizumab will help prevent the cancer from coming back. |
| Criteria: |
- A tumor that meets certain criteria for type, size and position;
- No history of intra-abdominal metastases;
- No perforation or obstruction of the bowel;
- Adequate liver, kidney, and heart function and/or laboratory values;
- No ulcers, or serious wounds or wound healing problems, bone fractures, or non-malignant systemic disease that would exclude them from the study;
- Biopsy of the tumor to evaluate two particular tumor markers;
- 18 years of age or older
|
| Contact: |
For Cancer Information, Current Clinical Trials, and Referral to a Physician please call (216) 844-5432 or (800) 641-2422 |
Participant Confidentiality:
All information regarding participation in Clinical Trials is treated with the
utmost confidentiality. University Hospitals Case Medical Center and the
Division of Clinical Research recognize and respect the confidentiality of this
information. Access to information related to clinical trials and their
participants is restricted to authorized clinical trials personnel only.
Back